 |
인쇄하기
취소
|
Janssen Korea to file application for new anticancer in early next year
Janssen Korea said it would file a new application for Velcade, proteasome inhibitor in early next year in line with its launching program.
The U.S. FDA announced on May 13 the approval of Velcade (bortezomib) injection, a new treatment for multiple myeloma, a cancer of the bone marrow. FDA reviewed the application for this drug in less than two months. Velcade is the first in a new class of...
The U.S. FDA announced on May 13 the approval of Velcade (bortezomib) injection, a new treatment for multiple myeloma, a cancer of the bone marrow. FDA reviewed the application for this drug in less than two months. Velcade is the first in a new class of...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.